

Reimbursement Policy

Diagnostic Testing of Common Sexually Transmitted Infections

[POLICY DESCRIPTION](#) | [INDICATIONS AND/OR LIMITATIONS OF COVERAGE](#) | [APPLICABLE STATE AND FEDERAL REGULATIONS](#) | [APPLICABLE CPT/HCPCS PROCEDURE CODES](#) | [EVIDENCE-BASED SCIENTIFIC REFERENCES](#) | [REVISION HISTORY](#)

I. Policy Description

Sexually transmitted infections (STIs), often referred to as sexually transmitted diseases or STDs, include a variety of pathogenic bacteria, virus, and other microorganisms that are spread through sexual contact and can cause a multitude of complications if left untreated. Chlamydia and gonorrhea, caused by *Chlamydia trachomatis* and *Neisseria gonorrhoeae*, respectively, have high rates of occurrence in the United States and can cause pelvic inflammatory disease (PID), infertility, and pregnancy complications. The causative agent of syphilis is *Treponema pallidum*; if left untreated, syphilis can lead to serious cardiac and neurological conditions.¹ Human papillomavirus (HPV) is a double-stranded DNA virus that can be sexually transmitted and is associated with cervical cancer, vulvar/vaginal cancer, anal cancer, oropharyngeal cancer, penile cancer, and both genital and nongenital warts. “Globally, anogenital HPV is the most common sexually transmitted infection” with an estimated 80% of sexually active adults exposed to it at least once in their lifetime.² Herpes simplex virus (HSV) is a common STI where many individuals are asymptomatic. HSV infection has been linked to an increased risk of other infections, including human immunodeficiency virus (HIV), and in rare cases, can also result in HSV meningitis or proctitis.³ In general, risk factors for STIs can include both behavioral elements, such as multiple sex partners, working in a sex trade, and inconsistent use of condoms when in non-monogamous relationships as well as demographic risks, including men who have sex with men (MSM), prior STI diagnosis, admission to correctional facilities, and lower socioeconomic status.¹

This policy is limited to testing for *C. trachomatis*, *N. gonorrhoeae*, *T. pallidum*, *T. vaginalis* (for guidance on panel testing for *T. vaginalis* in vaginitis, see AHS-M2057-Diagnosis of Vaginitis), HSV, and HPV. The following conditions and/or tests are discussed in the corresponding policies:

- Human Immunodeficiency Virus: AHS-M2116
- Hepatitis B and C: AHS-G2036-Hepatitis Testing
- Pediatric Preventive Screening: AHS-G2042
- Cervical Cancer Screening: AHS-G2002
- Pathogen Panel Testing: AHS-G2149

Reimbursement Policy

For STI screening in pregnant individuals, please see AHS-G2035-Prenatal Screening (Nongenetic).

II. Indications and/or Limitations of Coverage

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request. Specifications pertaining to Medicare and Medicaid can be found in the "Applicable State and Federal Regulations" section of this policy document.

- 1) Antibody testing for syphilis infection **MEETS COVERAGE CRITERIA** in the following situations:
 - a) For any asymptomatic person in a high-risk category (see Notes 1 & 2), once a year assessment using either a "standard" or "reverse" algorithm that includes initial and confirmatory tests for any initial positive test, such as:
 - i) Treponemal Ig test **and**
 - ii) Nontreponemal Ig test.
 - b) For diagnosis of any person presenting with signs and/or symptoms of a syphilis infection (see Note 3).
 - c) Once every three months for HIV-positive men or MSM.
 - d) Treponemal Ig testing and nontreponemal testing (once prior to transplant) as a part of a pre-transplant assessment in both donors and recipients of an allogeneic hematopoietic stem cell transplantation (allo-HCT).
 - e) When a nontreponemal test is used as a test of cure (TOC) for a positive syphilis infection.
- 2) For asymptomatic individuals NOT belonging to a high-risk category (see Notes 1 & 2), antibody screening for syphilis **MEETS COVERAGE CRITERIA** only in the following situations:
 - a) As part of newborn screening.
 - b) As part of follow-up in a victim of sexual assault.
 - c) For sexually active individuals less than 18 years of age (annually).
- 3) Polymerase chain reaction (PCR) testing and nucleic acid amplification testing (NAAT) for syphilis **DO NOT MEET COVERAGE CRITERIA**.
- 4) Qualitative NAAT for chlamydia **MEETS COVERAGE CRITERIA** in the following situations:

Reimbursement Policy

- a) Once a year assessment for any asymptomatic person in a high-risk category (see Notes 1 & 4).
 - b) For diagnosis of any person presenting with signs and/or symptoms of a chlamydial infection (see Note 5).
 - c) For the diagnosis of any person with suspected lymphogranuloma venereum (LGV).
 - d) At least three months after initial chlamydial diagnosis as a TOC.
- 5) For asymptomatic individuals NOT belonging to a high-risk category (see Notes 1 & 4), NAAT screening for chlamydia **MEETS COVERAGE CRITERIA** only in the following situations:
- a) As part of newborn screening.
 - b) As part of follow-up in a victim of sexual assault.
 - c) For sexually active individuals less than 18 years of age (annually).
- 6) Serology testing for chlamydia or LGV **DOES NOT MEET COVERAGE CRITERIA**.
- 7) Qualitative NAAT for gonorrhea **MEETS COVERAGE CRITERIA** in the following situations:
- a) Once a year assessment for any asymptomatic person in a high-risk category (see Notes 1 & 4).
 - b) For diagnosis of any person presenting with signs and/or symptoms of a gonorrheal infection (see Note 6).
 - c) As a TOC for treatment.
- 8) For an individual that does not respond to initial treatment, culture testing for *N. gonorrhoeae* to determine antimicrobial susceptibility **MEETS COVERAGE CRITERIA**.
- 9) For asymptomatic individuals NOT belonging to a high-risk category (see Notes 1 & 4), NAAT screening for gonorrhea **MEETS COVERAGE CRITERIA** only in the following situations:
- a) As part of newborn screening.
 - b) As part of follow-up in a victim of sexual assault.
 - c) For sexually active individuals less than 18 years of age (annually).
- 10) Qualitative NAAT for *T. vaginalis* **MEETS COVERAGE CRITERIA** in the following situations:
- a) For symptomatic individuals (see Note 7).
 - b) Follow up testing a minimum of three months after initial trichomoniasis diagnosis.

Reimbursement Policy

- c) Annual screening for asymptomatic individuals belonging to a high-risk group (see Note 8).
 - d) Annual screening for asymptomatic individuals who have an HIV infection.
 - e) As a part of follow-up in a victim of sexual assault.
- 11) Rapid identification of *Trichomonas* by enzyme immunoassay **DOES NOT MEET COVERAGE CRITERIA.**
- 12) For symptomatic individuals (see Note 8), testing for *Mycoplasma genitalium* using qualitative NAAT **MEETS COVERAGE CRITERIA.**
- 13) For asymptomatic individuals (see Note 9), screening for *M. genitalium* using NAAT **DOES NOT MEET COVERAGE CRITERIA.**
- 14) When an individual meets any of the conditions described above, multitarget PCR testing (targets limited to *C. trachomatis*, *N. gonorrhoeae*, *T. vaginalis*, and *M. genitalium*) **MEETS COVERAGE CRITERIA.**
- 15) For individuals with active genital ulcers or mucocutaneous lesions, qualitative NAAT for herpes simplex virus-1 (HSV-1) or herpes simplex virus-2 (HSV-2) **MEETS COVERAGE CRITERIA.**
- 16) Immunoassay testing for HSV-1 and and/or herpes simplex (non-specific type test) **DOES NOT MEET COVERAGE CRITERIA.**
- 17) Type-specific serologic testing for HSV-2 using a glycoprotein G2 (gG2) test **MEETS COVERAGE CRITERIA** in the following situations:
- a) Recurrent or atypical genital symptoms or lesions in individuals with a negative herpes simplex virus PCR or culture result.
 - b) For the clinical diagnosis of genital herpes in individuals with a negative PCR or culture result or without laboratory confirmation.
 - c) When an individual's partner has genital herpes.
- 18) In asymptomatic individuals, screening for HSV-1 or HSV-2 **DOES NOT MEET COVERAGE CRITERIA.**
- 19) In the diagnosis and/or assessment of cancer or cancer therapy (immunohistochemistry testing for p16 or NAAT testing for high-risk human papillomavirus [HR-HPV]), testing for HR-HPV **MEETS COVERAGE CRITERIA.**
- 20) Testing for HPV **DOES NOT MEET COVERAGE CRITERIA** in the following situations:

Reimbursement Policy

- a) To screen for oncogenic high-risk types, such as HPV-16 and HPV-18, as part of a general sexually transmitted disease (STD) or sexually transmitted infection (STI) screening process or panel for asymptomatic individuals.
 - b) As part of the diagnosis of anogenital warts.
 - c) Testing for low-risk types of HPV.
 - d) In the general population, either as a part of a panel of tests or as an individual NAAT to determine HPV status.
- 21) Prior to beginning a preexposure prophylaxis (PrEP) regimen, triple panel testing (hepatitis B surface antigen [HBsAg], hepatitis B surface antibody [anti-HBs], total antibody to hepatitis B core antigen [anti-HBc]) to screen for hepatitis B **MEETS COVERAGE CRITERIA.**
- 22) Prior to beginning or while an individual is undergoing a preexposure prophylaxis (PrEP) regimen for HIV prevention, the following screens/tests for additional STIs **MEET COVERAGE CRITERIA:**
- a) Qualitative NAAT screening for gonorrhea and chlamydia:
 - i) Once every three months for MSM.
 - ii) Once every six months for sexually active individuals.
 - b) Blood testing to screen for syphilis:
 - i) Once every three months for MSM.
 - ii) Once every six months for sexually active individuals.
- The following does not meet coverage criteria due to a lack of available published scientific literature confirming that the test(s) is/are required and beneficial for the diagnosis and treatment of an individual's illness.*
- 23) Nucleic acid testing to determine antimicrobial susceptibility in *N. gonorrhoeae* or macrolide resistance in *M. genitalium* **DOES NOT MEET COVERAGE CRITERIA.**
- 24) Direct probe detection and/or quantitative NAAT for the following microorganisms **DOES NOT MEET COVERAGE CRITERIA:**
- a) *Chlamydia trachomatis*
 - b) *Neisseria gonorrhoeae*
 - c) Herpes Simplex Virus-1
 - d) Herpes Simplex Virus-2
 - e) Human Papillomavirus

Reimbursement Policy

f) *Treponema pallidum*

NOTES:

Note 1: For sexually active children and adolescents under the age of 18, risk factors for chlamydia, gonorrhea, and/or syphilis infection as defined by the CDC include: initiating sex early in adolescence; living in detention facilities; receiving services at STD clinics; being involved in commercial sex exploitation or exchanging sex for drugs, money, food, or housing; having multiple sex partners, having sequential sex partnerships of limited duration or concurrent partnerships; failing to use barrier protection consistently and correctly; having lower socioeconomic status, and facing numerous obstacles to accessing healthcare. At-risk individuals also include: males who have sex with males (YMSM); transgender youths; youths with disabilities, substance abuse, or mental health disorders.⁴

Note 2: High-risk for Syphilis:^{5,6}

- Sexually active men who have sex with men (MSM)
- Sexually active individuals with an HIV-positive status
- Having a sexual partner recently diagnosed with a STI
- Exchanging sex for money or drugs
- Individuals in adult correctional facilities
- During pregnancy when the following risk factors are present:
 - Sexually active HIV-positive status
 - Sexually active with multiple partners
 - Sexually active in conjunction with drug use or transactional sex
 - Late entry to prenatal care (i.e., first visit during the second trimester or later) or no prenatal care
 - Methamphetamine or heroin use
 - Incarceration of the woman or her partner
 - Unstable housing or homelessness

Note 3: Signs and Symptoms of a Syphilis Infection:^{5,7}

- Chancre
- Skin rash and/or mucous membrane lesions in mouth, vagina, anus, hands, and feet
- Condyloma lata
- Secondary symptomology can include fever, fatigue, sore throat, swollen lymph nodes, weight loss, muscle aches, headache, and hair loss

Reimbursement Policy

- Signs and symptoms of neurosyphilis can include severe headache, trouble with muscle movements, muscle weakness or paralysis (not being able to move certain parts of the body), numbness, and changes in mental status (trouble focusing, confusion, personality change) and/or dementia (problems with memory, thinking, and/or making decisions).
- Signs and symptoms of ocular syphilis can include eye pain or redness, floating spots in the field of vision (“floaters”), sensitivity to light, and changes in vision (blurry vision or even blindness).
- Signs and symptoms of otosyphilis may include hearing loss, ringing, buzzing, roaring, or hissing in the ears (“tinnitus”), balance difficulties, and dizziness or vertigo.
- Signs and symptoms of late/tertiary syphilis include inflammatory lesions of the cardiovascular system (e.g., aortitis, coronary vessel disease), skin (e.g., gummatous lesions), and bone (e.g., osteitis).

Note 4: High-risk for Chlamydia and/or Gonorrhea:⁸⁻¹¹

- Sexually active men who have sex with men (MSM)
- Sexually active individuals with an HIV-positive status
- Sexually active individuals with a cervix who are under the age of 25
- Individuals with a cervix who are 25 years of age or older and who have multiple sexual partners
- Having a sexual partner recently diagnosed with an STI
- Previous or concurrent STI
- Exchanging sex for money or drugs

Note 5: Signs and Symptoms of a Chlamydia Infection:^{8,11}

- Genital symptoms, including “discharge, burning during urination, unusual sores, or rash”
- Pelvic Inflammatory Disease (PID), including “symptoms of abdominal and/or pelvic pain, along with signs of cervical motion tenderness, and uterine or adnexal tenderness on examination”
- Urethritis
- Pyuria
- Dysuria
- Increase in frequency in urination
- Epididymitis (with or without symptomatic urethritis) in men
- Proctitis
- Sexually acquired chlamydial conjunctivitis

Note 6: Signs and Symptoms of Gonorrhea:¹⁰

- Dysuria

Reimbursement Policy

- Urethral infection
- Urethral or vaginal discharge
- Epididymitis (Testicular or scrotal pain)
- Rectal infection symptoms include anal itching, discharge, rectal bleeding, and painful bowel movements

Note 7: Signs and Symptoms of Trichomoniasis:¹²

- Vaginal or penile discharge
- Itching, irritation, a burning sensation, or soreness of the genitalia
- Discomfort or burning sensation during/after urination and/or ejaculation
- Urethritis
- Epididymitis
- Prostatitis

Note 8: High-risk for Trichomoniasis:¹³

- Receiving care in high-prevalence settings (e.g., STI clinics, correctional facilities)
- Having multiple sexual partners
- Exchanging sex for money or drugs
- Having a previous or concurrent STI
- Drug misuse
- History of incarceration
- Sexually active individuals with an HIV-positive status

Note 9: Signs and Symptoms of *M. genitalium* Infection:¹⁴

- When present, typical symptoms of *Mgen*-urethritis in men include dysuria, urethral pruritus, and purulent or mucopurulent urethral discharge.
- When present, typical symptoms of *Mgen* cervicitis in women include vaginal discharge, vaginal itching, dysuria, and pelvic discomfort.
- When present, typical symptoms of PID due to *Mgen* include mild to severe pelvic pain, abdominal pain, abnormal vaginal discharge, and/or bleeding.

III. Applicable State and Federal Regulations

DISCLAIMER: If there is a conflict between this Policy and any relevant, applicable government policy for a particular member [e.g., Local Coverage Determinations (LCDs) or National Coverage Determinations (NCDs) for Medicare and/or state coverage for Medicaid], then the government policy will be used to make the determination. For the most up-to-date Medicare policies and coverage, please visit the Medicare search website: <https://www.cms.gov/medicare->

Reimbursement Policy

[coverage-database/search.aspx](#). For the most up-to-date Medicaid policies and coverage, visit the applicable state Medicaid website.

Food and Drug Administration (FDA)

The FDA has approved many tests for HSV, chlamydia, gonorrhea, and syphilis. Some of these tests are discussed in the “Proprietary Testing” section of this policy. In addition to these tests, many labs have developed specific tests that they must validate and perform in house. These laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid (CMS) as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88). LDTs are not approved or cleared by the U. S. Food and Drug Administration; however, FDA clearance or approval is not currently required for clinical use.

IV. Applicable CPT/HCPCS Procedure Codes

CPT	Code Description
86592	Syphilis test, non-treponemal antibody; qualitative (eg, VDRL, RPR, ART)
86593	Syphilis test, non-treponemal antibody; quantitative
86631	Antibody; Chlamydia
86632	Antibody; Chlamydia, IGM
86694	Antibody; herpes simplex, non-specific type test
86695	Antibody; herpes simplex, type 1
86696	Antibody; herpes simplex, type 2
86704	Hepatitis B core antibody (HBcAb); total
86706	Hepatitis B surface antibody (HBsAb)
86780	Antibody; Treponema pallidum
87081	Culture, presumptive, pathogenic organisms, screening only
87110	Culture, Chlamydia, any source
87181	Susceptibility studies, antimicrobial agent; agar dilution method, per agent (e.g., antibiotic gradient strip)
87340	Infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; hepatitis B surface antigen (HBsAg)
87490	Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, direct probe technique
87491	Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique
87492	Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, quantification

Reimbursement Policy

CPT	Code Description
87528	Infectious agent detection by nucleic acid (DNA or RNA); Herpes simplex virus, direct probe technique
87529	Infectious agent detection by nucleic acid (DNA or RNA); Herpes simplex virus, amplified probe technique
87530	Infectious agent detection by nucleic acid (DNA or RNA); Herpes simplex virus, quantification
87563	Infectious agent detection by nucleic acid (DNA or RNA); Mycoplasma genitalium, amplified probe technique
87590	Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, direct probe technique
87591	Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique
87592	Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, quantification
87623	Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), low-risk types (e.g., 6, 11, 42, 43, 44)
87624	Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68), pooled result
87625	Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), types 16 and 18 only, includes type 45, if performed
87626	Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), separately reported high-risk types (eg, 16, 18, 31, 45, 51, 52) and high-risk pooled result(s)
87661	Infectious agent detection by nucleic acid (DNA or RNA); Trichomonas vaginalis, amplified probe technique
87797	Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; direct probe technique, each organism
87798	Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; amplified probe technique, each organism
87799	Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; quantification, each organism
87800	Infectious agent detection by nucleic acid (DNA or RNA), multiple organisms; direct probe(s) technique
87808	Infectious agent antigen detection by immunoassay with direct optical (i.e., visual) observation; Trichomonas vaginalis
88341	Immunohistochemistry or immunocytochemistry, per specimen; each additional single antibody stain procedure (list separately in addition to code for primary procedure)

Reimbursement Policy

CPT	Code Description
88342	Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure
88344	Immunohistochemistry or immunocytochemistry, per specimen; each multiplex antibody stain procedure
0064U	Antibody, Treponema pallidum, total and rapid plasma reagin (RPR), immunoassay, qualitative Proprietary test: BioPlex 2200 Syphilis Total & RPR Assay Lab/Manufacturer: Bio-Rad Laboratories
0065U	Syphilis test, non-treponemal antibody, immunoassay, qualitative (RPR) Proprietary test: BioPlex 2200 RPR Assay Lab/Manufacturer: Bio-Rad Laboratories
0096U	Human papillomavirus (HPV), high-risk types (i.e., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68), male urine Proprietary test: HPV, High-Risk, Male Urine Lab/Manufacturer: Molecular Testing Labs/Roche Cobas
0210U	Syphilis test, non-treponemal antibody, immunoassay, quantitative (RPR) Proprietary test: BioPlex 2200 RPR Assay - Quantitative Lab/Manufacturer: Bio-Rad Laboratories
0402U	Infectious agent (sexually transmitted infection), Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium, multiplex amplified probe technique, vaginal, endocervical, or male urine, each pathogen reported as detected or not detected Proprietary test: Abbott Alinity™ m STI Assay Lab/Manufacturer: Abbott Molecular, Inc
0455U	Infectious agents (sexually transmitted infection), Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis, multiplex amplified probe technique, vaginal, endocervical, gynecological specimens, oropharyngeal swabs, rectal swabs, female or male urine, each pathogen reported as detected or not detected Proprietary test: Abbott Alinity™ m STI Assay Lab/Manufacturer: Abbott Molecular, Inc
0463U	Oncology (cervix), mRNA gene expression profiling of 14 biomarkers (E6 and E7 of the highest-risk human papillomavirus [HPV] types 16, 18, 31, 33, 45, 52, 58), by real-time nucleic acid sequence-based amplification (NASBA), exo- or endocervical epithelial cells, algorithm reported as positive or negative for increased risk of cervical dysplasia or cancer for each biomarker Proprietary test: Proofer '7 HPV mRNA E6 and E7 Biomarker Test Lab/Manufacturer: Global Diagnostics Labs, LLC, PreTect AS, a Mel-Mont Medical, Inc

Reimbursement Policy

CPT	Code Description
0483U	Infectious disease (Neisseria gonorrhoeae), sensitivity, ciprofloxacin resistance (gyrA S91F point mutation), oral, rectal, or vaginal swab, algorithm reported as probability of fluoroquinolone resistance Proprietary test: Ciprofloxacin Susceptibility of Neisseria gonorrhoeae Lab/Manufacturer: MedArbor Diagnostics, Speedx, Inc
0484U	Infectious disease (Mycoplasma genitalium), macrolide sensitivity (23S rRNA point mutation), oral, rectal, or vaginal swab, algorithm reported as probability of macrolide resistance Proprietary test: Macrolide Resistance of Mycoplasma genitalium Lab/Manufacturer: MedArbor Diagnostics, Speedx, Inc
G0499	Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (HBSAG) followed by a neutralizing confirmatory test for initially reactive results, and antibodies to HBSAG (anti-HBs) and Hepatitis B core antigen (anti-HBc)

Current Procedural Terminology© American Medical Association. All Rights reserved.

Procedure codes appearing in Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.

V. Evidence-based Scientific References

1. Ghanem KG, Tuddenham S. Screening for sexually transmitted infections. Updated May 13, 2025. <https://www.uptodate.com/contents/screening-for-sexually-transmitted-infections>
2. Palefsky JM. Human papillomavirus infections: Epidemiology and disease associations. Updated February 25, 2025. <https://www.uptodate.com/contents/human-papillomavirus-infections-epidemiology-and-disease-associations>
3. Albrecht MA. Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection. Updated October 28, 2024. <https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-infection>
4. CDC. Sexually Transmitted Infections Treatment Guidelines, 2021 - Adolescents. Updated July 22, 2021. <https://www.cdc.gov/std/treatment-guidelines/adolescents.htm>
5. CDC. About Syphilis. Updated January 30, 2025. <https://www.cdc.gov/syphilis/about/index.html>
6. Cantor AG, Pappas M, Daeges M, Nelson HD. Screening for syphilis: Updated evidence report and systematic review for the us preventive services task force. *JAMA*. 2016;315(21):2328-2337. doi:10.1001/jama.2016.4114
7. CDC. Syphilis (Treponema pallidum): 2018 Case Definition. Updated August 16, 2021. <https://ndc.services.cdc.gov/case-definitions/syphilis-2018/>
8. CDC. About Chlamydia. Updated January 31, 2025. <https://www.cdc.gov/chlamydia/about/index.html>

Reimbursement Policy

9. LeFevre ML. Screening for Chlamydia and gonorrhea: U.S. Preventive Services Task Force recommendation statement. *Annals of internal medicine*. Dec 16 2014;161(12):902-10. doi:10.7326/m14-1981
10. CDC. About Gonorrhea. Updated January 31, 2025. <https://www.cdc.gov/gonorrhea/about/index.html>
11. CDC. Sexually Transmitted Infections Treatment Guidelines, 2021. Updated July 23, 2021. <https://www.cdc.gov/std/treatment-guidelines/STI-Guidelines-2021.pdf>
12. CDC. About Trichomoniasis. Updated January 31, 2025. <https://www.cdc.gov/trichomoniasis/about/index.html>
13. CDC. Screening Recommendations and Considerations Referenced in Treatment Guidelines and Original Sources. Updated March 22, 2024. <https://www.cdc.gov/std/treatment-guidelines/screening-recommendations.htm>
14. CDC. Mycoplasma genitalium. Updated July 22, 2021. <https://www.cdc.gov/std/treatment-guidelines/mycoplasmagenitalium.htm>
15. Hsu K. Clinical manifestations and diagnosis of Chlamydia trachomatis infections in adults and adolescents. Updated May 1, 2024. <https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chlamydia-trachomatis-infections-in-adults-and-adolescents>
16. CDC. Table 28. Chlamydia — Reported Cases and Rates of Reported Cases by State, Ranked by Rates, United States, 2023. Updated November 12, 2024. <https://www.cdc.gov/sti-statistics/data-vis/table-ct-state-ranked.html>
17. Goldstein E, Martinez-García L, Obermeier M, et al. Simultaneous identification of Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, and Trichomonas vaginalis—multicenter evaluation of the Alinity m STI assay. *Journal of Laboratory Medicine*. 2021;45(4-5):213-223. doi:10.1515/labmed-2020-0136
18. Ghanem KG. Clinical manifestations and diagnosis of Neisseria gonorrhoeae infection in adults and adolescents. Updated July 8, 2024. <https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-neisseria-gonorrhoeae-infection-in-adults-and-adolescents>
19. Unemo M, Ross J, Serwin AB, Gomberg M, Cusini M, Jensen JS. 2020 European guideline for the diagnosis and treatment of gonorrhoea in adults. *International journal of STD & AIDS*. Oct 29 2020;956462420949126. doi:10.1177/0956462420949126
20. CDC. The State of STIs - Infographic & Graphics. Updated April 3, 2024. <https://www.cdc.gov/sti/php/communication-resources/the-state-of-stis.html>
21. Hicks CB, Clement M. Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV. Updated December 20, 2023. <https://www.uptodate.com/contents/syphilis-epidemiology-pathophysiology-and-clinical-manifestations-in-patients-without-hiv>
22. Hicks CB, Clement M. Syphilis: Screening and diagnostic testing. Updated August 21, 2024. <https://www.uptodate.com/contents/syphilis-screening-and-diagnostic-testing>
23. Janier M, Hegyi V, Dupin N, et al. 2014 European guideline on the management of syphilis. *Journal of the European Academy of Dermatology and Venereology : JEADV*. Dec 2014;28(12):1581-93. doi:10.1111/jdv.12734

Reimbursement Policy

24. Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. *MMWR Recommendations and reports : Morbidity and mortality weekly report Recommendations and reports*. Jun 5 2015;64(Rr-03):1-137.
25. CDC. About Genital Herpes. Updated February 20, 2024. <https://www.cdc.gov/herpes/about/index.html>
26. Riley LE, Wald A. Genital herpes simplex virus infection and pregnancy. Updated October 17, 2024. <https://www.uptodate.com/contents/genital-herpes-simplex-virus-infection-and-pregnancy>
27. CDC. About Genital HPV Infection. Updated January 31, 2025. <https://www.cdc.gov/sti/about/about-genital-hpv-infection.html>
28. Feldman S, Crum CP. Cervical cancer screening tests: Techniques for cervical cytology and human papillomavirus testing. Updated June 24, 2025. <https://www.uptodate.com/contents/cervical-cancer-screening-tests-techniques-for-cervical-cytology-and-human-papillomavirus-testing>
29. USPSTF. Genital Herpes Infection: Serologic Screening. Updated February 14, 2023. <https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/genital-herpes-serologic-screening>
30. USPSTF. Prevention of Acquisition of HIV: Preexposure Prophylaxis. Updated August 22, 2023. <https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prevention-of-human-immunodeficiency-virus-hiv-infection-pre-exposure-prophylaxis#citation47>
31. WHO. Global HIV & AIDS statistics — Fact sheet. <https://www.unaids.org/en/resources/fact-sheet>
32. CDC. Clinical Guidance for PrEP. Updated February 10, 2025. <https://www.cdc.gov/hivnexus/hcp/prep/index.html>
33. BD. BD receives FDA Approval for HPV Test with Extended Genotyping Capabilities. <https://www.bd.com/en-us/company/news-and-media/press-releases/july-22-2020-bd-receives-fda-approval-for-hpv-test-with-extended-genotyping-capabilities>
34. FDA. BD ONCLARITY HPV ASSAY. <https://www.accessdata.fda.gov/scripts/cdrh/devicesatfda/index.cfm?db=pma&id=391601>
35. FDA. 501(k) Premarket Notification Xpert CT/NG. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K121710>
36. FDA. 501(k) Premarket Notification Xpert CT/NG, GeneXpert Dx System, GeneXpert Infinity-48s and GeneXpert Infinity-80 Systems, GeneXpert Infinity-48 System, Xpert Vaginal/Endocervical Specimen Collection, Xpert Urine Specimen Collection Kit, Xpert Swab Specimen Collection Kit. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K190441>
37. FDA. 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY K121710. https://www.accessdata.fda.gov/cdrh_docs/reviews/K121710.pdf
38. FDA. 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY K190441. https://www.accessdata.fda.gov/cdrh_docs/reviews/K190441.pdf

Reimbursement Policy

39. Cepheid. Xpert® CT/NG. <https://www.cephheid.com/Package%20Insert%20Files/Xpert-CTNG-US-ENGLISH-Package-Insert-301-0234--Rev-K.pdf>
40. Abbott. Alinity m STI AMP Kit. <https://www.molecularcatalog.abbott/int/en/alinity-m-sti-assay>
41. Cook RL, Hutchison SL, Ostergaard L, Braithwaite RS, Ness RB. Systematic review: noninvasive testing for Chlamydia trachomatis and Neisseria gonorrhoeae. *Annals of internal medicine*. Jun 7 2005;142(11):914-25. doi:10.7326/0003-4819-142-11-200506070-00010
42. Golden M, O'Donnell M, Lukehart S, et al. Treponema pallidum Nucleic Acid Amplification Testing To Augment Syphilis Screening among Men Who Have Sex with Men. *J Clin Microbiol*. Aug 2019;57(8)doi:10.1128/jcm.00572-19
43. Wong EH, Klausner JD, Caguin-Grygiel G, et al. Evaluation of an IgM/IgG sensitive enzyme immunoassay and the utility of index values for the screening of syphilis infection in a high-risk population. *Sexually transmitted diseases*. Jun 2011;38(6):528-32. doi:10.1097/OLQ.0b013e318205491a
44. Tsang RS, Martin IE, Lau A, Sawatzky P. Serological diagnosis of syphilis: comparison of the Trep-Chek IgG enzyme immunoassay with other screening and confirmatory tests. *FEMS immunology and medical microbiology*. Oct 2007;51(1):118-24. doi:10.1111/j.1574-695X.2007.00289.x
45. Juarez-Figueroa L, Uribe-Salas F, Garcia-Cisneros S, Olamendi-Portugal M, Conde-Glez CJ. Evaluation of a rapid strip and a particle agglutination tests for syphilis diagnosis. *Diagnostic microbiology and infectious disease*. Oct 2007;59(2):123-6. doi:10.1016/j.diagmicrobio.2007.04.008
46. Feltner C, Grodensky C, Ebel C, et al. Serologic Screening for Genital Herpes: An Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA*. Dec 20 2016;316(23):2531-2543. doi:10.1001/jama.2016.17138
47. Glass N, Nelson, Heidi D. Screening for Genital Herpes Simplex: A Brief Update for the U.S. Preventive Services Task Force. Updated December 20, 2023. <https://www.uspreventiveservicestaskforce.org/Home/GetFile/1/733/herpesup/pdf>
48. Castle PE, Stoler MH, Wright TC, Jr., Sharma A, Wright TL, Behrens CM. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. *The Lancet Oncology*. Sep 2011;12(9):880-90. doi:10.1016/s1470-2045(11)70188-7
49. Guenat D, Launay S, Riethmuller D, Mougin C, Pretet JL. Validation of Novaprep((R)) HQ+ liquid-based cytology medium for high-risk human papillomavirus detection by hc2. *Infectious agents and cancer*. 2016;11:41. doi:10.1186/s13027-016-0092-7
50. Tshomo U, Franceschi S, Tshokey T, et al. Evaluation of the performance of Human Papillomavirus testing in paired urine and clinician-collected cervical samples among women aged over 30 years in Bhutan. *Virology journal*. Apr 8 2017;14(1):74. doi:10.1186/s12985-017-0744-2
51. Pham MD, Wise A, Garcia ML, et al. Improving the coverage and accuracy of syphilis testing: The development of a novel rapid, point-of-care test for confirmatory testing of

Reimbursement Policy

- active syphilis infection and its early evaluation in China and South Africa. *EClinicalMedicine*. Jul 2020;24:100440. doi:10.1016/j.eclinm.2020.100440
52. Bristow CC, Morris SR, Little SJ, Mehta SR, Klausner JD. Meta-analysis of the Cepheid Xpert(®) CT/NG assay for extragenital detection of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) infections. *Sex Health*. Aug 2019;16(4):314-319. doi:10.1071/sh18079
53. Cosentino LA, Danby CS, Rabe LK, et al. Use of Nucleic Acid Amplification Testing for Diagnosis of Extragenital Sexually Transmitted Infections. *J Clin Microbiol*. Sep 2017;55(9):2801-2807. doi:10.1128/jcm.00616-17
54. Kelly H, Coltart CEM, Pant Pai N, et al. Systematic reviews of point-of-care tests for the diagnosis of urogenital Chlamydia trachomatis infections. *Sexually transmitted infections*. Dec 2017;93(S4):S22-s30. doi:10.1136/sextrans-2016-053067
55. Guy RJ, Causer LM, Klausner JD, et al. Performance and operational characteristics of point-of-care tests for the diagnosis of urogenital gonococcal infections. *Sexually transmitted infections*. Dec 2017;93(S4):S16-s21. doi:10.1136/sextrans-2017-053192
56. Brischetto A, Gassiep I, Whiley D, Norton R. Retrospective Review of Treponema pallidum PCR and Serology Results: Are Both Tests Necessary? *J Clin Microbiol*. May 2018;56(5)doi:10.1128/jcm.01782-17
57. Zhiyan L, Meiling W, Ping L, Jinhua D, Zhenlin Y, Zhenru F. Consistency Between Treponema pallidum Particle Agglutination Assay and Architect Chemiluminescent Microparticle Immunoassay and Characterization of Inconsistent Samples. *Journal of clinical laboratory analysis*. Jul 2015;29(4):281-4. doi:10.1002/jcla.21765
58. Liu TY, Xie R, Luo L, et al. Diagnostic validity of human papillomavirus E6/E7 mRNA test in cervical cytological samples. *Journal of virological methods*. Feb 2014;196:120-5. doi:10.1016/j.jviromet.2013.10.032
59. Yao YL, Tian QF, Cheng B, Cheng YF, Ye J, Lu WG. Human papillomavirus (HPV) E6/E7 mRNA detection in cervical exfoliated cells: a potential triage for HPV-positive women. *Journal of Zhejiang University Science B*. Mar. 2017;18(3):256-262. doi:10.1631/jzus.B1600288
60. Arbyn M, Roelens J, Simoons C, et al. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions. *The Cochrane database of systematic reviews*. Mar 28 2013;(3):Cd008054. doi:10.1002/14651858.CD008054.pub2
61. Gaydos CA, Ako MC, Lewis M, Hsieh YH, Rothman RE, Dugas AF. Use of a Rapid Diagnostic for Chlamydia trachomatis and Neisseria gonorrhoeae for Women in the Emergency Department Can Improve Clinical Management: Report of a Randomized Clinical Trial. *Ann Emerg Med*. Jul 2019;74(1):36-44. doi:10.1016/j.annemergmed.2018.09.012
62. NCCN. NCCN Clinical Practice Guidelines in Oncology Anal Carcinoma. Updated May 30, 2025. https://www.nccn.org/professionals/physician_gls/pdf/anal.pdf

Reimbursement Policy

63. Marcell AV, Health MTCffPaR. Preventive Male Sexual and Reproductive Health Care: Recommendations for Clinical Practice. <https://californiaptc.com/wp-content/uploads/2019/12/Preventative-Male-Sexual-and-Reproductive-Health-Care.pdf>
64. NCCN. NCCN Clinical Practice Guidelines in Oncology Cervical Cancer. Updated March 24, 2025. https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf
65. NCCN. NCCN Clinical Practice Guidelines in Oncology Head and Neck Cancers Updated August 12, 2025. https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf
66. NCCN. NCCN Clinical Practice Guidelines Occult Primary (Cancer of Unknown Primary [CUP]). Updated September 11, 2024. https://www.nccn.org/professionals/physician_gls/pdf/occult.pdf
67. NCCN. NCCN Clinical Practice Guidelines in Oncology Penile Cancer Updated January 6, 2025. https://www.nccn.org/professionals/physician_gls/pdf/penile.pdf
68. NCCN. NCCN Clinical Practice Guidelines in Oncology Vulvar Cancer (Squamous Cell Carcinoma). Updated February 10, 2025. https://www.nccn.org/professionals/physician_gls/pdf/vulvar.pdf
69. USPSTF. Chlamydia and Gonorrhea: Screening. Updated September 14, 2021. <https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/chlamydia-and-gonorrhea-screening>
70. Moyer VA. Screening for oral cancer: U.S. preventive services task force recommendation statement. *Annals of internal medicine*. 2014;160(1):55-60. doi:10.7326/M13-2568
71. Force UPST. Screening for Syphilis Infection in Nonpregnant Adolescents and Adults: US Preventive Services Task Force Reaffirmation Recommendation Statement. *JAMA*. 2022;328(12):1243-1249. doi:10.1001/jama.2022.15322
72. Force UPST. Screening for Syphilis Infection During Pregnancy: US Preventive Services Task Force Reaffirmation Recommendation Statement. *JAMA*. 2025;333(22):2006-2012. doi:10.1001/jama.2025.5009
73. CDC. Clinical Guidance for STIs. Updated July 18, 2025. <https://www.cdc.gov/sti/hcp/clinical-guidance/index.html>
74. Papp JR PI, Fakile Y, Pereira L, Pillay A, Bolan GA. CDC Laboratory Recommendations for Syphilis Testing. *CDC MMWR Recomm Rep* 2024. 2024;73(No. RR-1):1–32doi:10.15585/mmwr.rr7301a1
75. CDC. Neurosyphilis, Ocular Syphilis, and Ootosyphilis. Updated March 7, 2024. <https://www.cdc.gov/syphilis/hcp/neurosyphilis-ocular-syphilis-otosyphilis/>
76. Dykewicz CA, Jaffe HW, Kaplan JE. Guidelines for Preventing Opportunistic Infections Among Hematopoietic Stem Cell Transplant Recipients. <https://www.cdc.gov/mmwr/preview/mmwrhtml/rr4910a1.htm>
77. CDC. Drug-Resistant Gonorrhea. Updated February 15, 2024. <https://www.cdc.gov/gonorrhea/hcp/drug-resistant/index.html>
78. CDC. Gonococcal Isolate Surveillance Project (GISP) Profiles. Updated April 15, 2025. <https://www.cdc.gov/sti-statistics/gisp-profiles/index.html>

Reimbursement Policy

79. Papp JR, Schachter J, Gaydos CA, Van Der Pol B. Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae--2014. *MMWR Recommendations and reports : Morbidity and mortality weekly report Recommendations and reports*. Mar 14 2014;63(Rr-02):1-19.
80. CDC. HPV & Men Fact Sheet. Updated April 18, 2022. https://www.ihs.gov/sites/nptc/themes/responsive2017/display_objects/documents/sti_community/CDC-%20STD%20Facts%20-%20HPV%20and%20Men.pdf
81. CDC. Trichomoniasis. Updated September 21, 2022. <https://www.cdc.gov/std/treatment-guidelines/trichomoniasis.htm>
82. CDC. Sexual Assault and Abuse and STIs – Adolescents and Adults. Updated July 22, 2021. <https://www.cdc.gov/std/treatment-guidelines/sexual-assault-adults.htm>
83. Gilson R, Nugent D, Werner RN, Ballesteros J, Ross J. 2019 IUSTI-Europe guideline for the management of anogenital warts. *Journal of the European Academy of Dermatology and Venereology : JEADV*. Aug 2020;34(8):1644-1653. doi:10.1111/jdv.16522
84. de Vries HJC, de Barbeyrac B, de Vrieze NHN, et al. 2019 European guideline on the management of lymphogranuloma venereum. *Journal of the European Academy of Dermatology and Venereology : JEADV*. Oct 2019;33(10):1821-1828. doi:10.1111/jdv.15729
85. Janier M, Unemo M, Dupin N, Tiplica GS, Potocnik M, Patel R. 2020 European guideline on the management of syphilis. *Acta Clin Belg*. Jun 6 2020;doi:10.1080/17843286.2020.1773112
86. Lanjouw E, Ouburg S, de Vries HJ, Stary A, Radcliffe K, Unemo M. 2015 European guideline on the management of Chlamydia trachomatis infections. *International journal of STD & AIDS*. Apr 2016;27(5):333-48. doi:10.1177/0956462415618837
87. Patel R, Kennedy OJ, Clarke E, et al. 2017 European guidelines for the management of genital herpes. *International journal of STD & AIDS*. Dec 2017;28(14):1366-1379. doi:10.1177/0956462417727194
88. Public Health Agency of Canada. Anogenital warts guide: Key information and resources. Public Health Agency of Canada. Updated February 20 2025. <https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines/anogenital-warts.html>
89. Public Health Agency of Canada. Chlamydia and LGV guide: Key information and resources. Updated February 20 2025. <https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines/chlamydia-lgv.html>
90. Public Health Agency of Canada. Genital herpes guide: Key information and resources. Updated December 12, 2021. <https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines/herpes-simplex-virus.html>

Reimbursement Policy

91. Public Health Agency of Canada. Gonorrhea guide: Key information and resources. Updated December 23, 2024. <https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines/gonorrhea.html>
92. Public Health Agency of Canada. Mycoplasma Genitalium guide: Key information and resources. Updated December 22, 2021. <https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines/mycoplasma-genitalium.html>
93. Public Health Agency of Canada. Syphilis guide: Key information and resources. Updated April 15, 2025. <https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines/syphilis.html>
94. Murray P, Braverman P, Adelman W, et al. Screening for nonviral sexually transmitted infections in adolescents and young adults. *Pediatrics*. Jul 2014;134(1):e302-11. doi:10.1542/peds.2014-1024
95. NICE. National Institute for Health and Care Excellence: Clinical Guidelines. *Cancer of the Upper Aerodigestive Tract: Assessment and Management in People Aged 16 and Over*. National Institute for Health and Care Excellence (UK) Copyright (c) National Collaborating Centre for Cancer.; 2018.
96. NICE. Reducing sexually transmitted infections. Updated June 15, 2022. <https://www.nice.org.uk/guidance/ng221>
97. Society CP. Diagnosis and management of congenital syphilis – Avoiding missed opportunities. Updated March 28, 2024. <https://www.cps.ca/en/documents/position/congenital-syphilis>
98. Canadian Paediatric Society. Comprehensive sexual health assessments for adolescents. Updated December 7, 2020. <https://cps.ca/en/documents/position/comprehensive-sexual-health-assessments-for-adolescents>
99. White J, O'Farrell N, Daniels D. 2013 UK National Guideline for the management of lymphogranuloma venereum: Clinical Effectiveness Group of the British Association for Sexual Health and HIV (CEG/BASHH) Guideline development group. *International journal of STD & AIDS*. Aug 2013;24(8):593-601. doi:10.1177/0956462413482811
100. Patel R, Green J, Clarke E, et al. 2014 UK national guideline for the management of anogenital herpes. *International journal of STD & AIDS*. Oct 2015;26(11):763-76. doi:10.1177/0956462415580512
101. Nwokolo NC, Dragovic B, Patel S, Tong CY, Barker G, Radcliffe K. 2015 UK national guideline for the management of infection with Chlamydia trachomatis. *International journal of STD & AIDS*. Mar 2016;27(4):251-67. doi:10.1177/0956462415615443
102. BASHH. Update on the treatment of Chlamydia trachomatis (CT) infection. <https://www.bashh.org/userfiles/pages/files/resources/updateonthetreatmentofchlamydiastrachomatisinfectionfinal16918.pdf>
103. Kingston M, French P, Higgins S, et al. UK national guidelines on the management of syphilis 2015. *International journal of STD & AIDS*. May 2016;27(6):421-46. doi:10.1177/0956462415624059

Reimbursement Policy

104. Ullmann AJ, Schmidt-Hieber M, Bertz H, et al. Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. *Ann Hematol*. Sep 2016;95(9):1435-55. doi:10.1007/s00277-016-2711-1

VI. Revision History

Revision Date	Summary of Changes
09/04/2025	Reviewed and Updated: Updated the background, guidelines and recommendations, and evidence-based scientific references. Literature review necessitated the following changes to coverage criteria: For clarity, added “qualitative” to “qualitative NAAT” in CC4, CC7, CC10, CC12, CC15 CC5, CC20.c., and Note 2 edited for clarity Individual organism amplified probe testing for <i>T. vaginalis</i> now solely addressed in this policy, with multi-organism vaginitis panels that also test for <i>T. vaginalis</i> remaining in M2057. Results in expansion of CC10 and new Note 8. CC10 now reads: “10) Qualitative NAAT for <i>T. vaginalis</i> MEETS COVERAGE CRITERIA in the following situations: a) For symptomatic individuals (see Note 7). b) Follow up testing a minimum of three months after initial trichomoniasis diagnosis. c) Annual screening for asymptomatic individuals belonging to a high-risk group (see Note 8). d) Annual screening for asymptomatic individuals who have an HIV infection. e) As a part of follow-up in a victim of sexual assault.” CC21 and CC22 updated to focus on the recommended STI screens for individuals being considered for or actively receiving PrEP. Removed references to screens outside of STIs other than HIV (e.g., measurement of creatine, pregnancy testing); HIV screening recommendations for this population now fully addressed in M2116. CC24 updated to include direct probe detection. Now reads: “24) Direct probe detection and/or quantitative NAAT for the following microorganisms DOES NOT MEET COVERAGE CRITERIA:” Note 4 and Note 7 updated to align with CDC. New Note 8: “Note 8: High-risk for Trichomoniasis: • Receiving care in high-prevalence settings (e.g., STI clinics, correctional facilities)

Reimbursement Policy

	• Having multiple sexual partners • Exchanging sex for money or drugs • Having a previous or concurrent STI • Drug misuse • History of incarceration • Sexually active individuals with an HIV-positive status” Added CPT code 87800 Removed CPT code 82565, 82575, 84702, 84703, 86701, 86702, 86703, 86705, 86803, 86804, 87660, G0432, G0433, G0435, G0472, G0475, S3645
12/04/2024	Off-Cycle Coding Modification: Added CPT code 87626 (effective date 1/1/2025) Removed CPT code 0500T (deleted code; effective date 1/1/2025) Revised code description for CPT code 87624 (effective date 1/1/2025)